Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
INTELLIGENT BIO SOLUTIONS INC (INBS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$1.76+0.57%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for INBS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain gross margin near 50.5% | A supporting condition in INTELLIGENT BIO SOLUTIONS INC's published investment case. The stated target is >=50.5%. | Broken | Gross margin falls below 45% next year | Gross margin: 46.83% FY2026-Q4; GAAP. Published target: >=50.5%. The stored target says 2026-Q1; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Nov 2, 202646.830342 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making growth business, not a proven compounder. Its long-term thesis is on watch: commercial growth and margin gains are tangible, while recent performance remains weak relative to its industry cohort.
INBS is described as cheap versus peers, but the model has low confidence and the expectations gap is negative. The evidence does not show that low peer valuation removes the risk from continued losses or weak performance; the priced-in signal is marked justified, with low fragility.
Over the multi-year view, revenue and cartridge volumes have grown, and full-year gross margin improved, supporting management’s commercial-growth and operational priorities. Near term, the risk of an earnings miss is elevated after recent misses, despite the August earnings beat; a guidance cut would add pressure to the business outlook. FDA 510(k) progress is meaningful, but the evidence gives no financial measure of its effect.
The thesis depends on sustaining commercial growth and margin improvement while advancing U.S. market entry through the 510(k) process. Near term, guidance and earnings execution are key swing factors. A weakening jobs trend could weigh on cyclical healthcare names, while continued strong results and guidance from sector bellwethers could support sector momentum.
For the next 1 to 3 years, INBS offers evidence of operating progress, but losses, weak recent performance, and elevated miss risk leave the long-term thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in INTELLIGENT BIO SOLUTIONS INC's published investment case. The stated target is EPS loss narrows from -$5.18 in FY27. |
| Broken |
| EPS loss worsens beyond -$6.00 in FY27 |
Diluted EPS: $-1.34 per share FY2026-Q4; GAAP. Published target: EPS loss narrows from -$5.18 in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 19, 2026-1.34 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Grow revenue by 36% year-over-year | INBS aims to grow revenue 36% year-over-year. | Improving | YoY revenue growth falls below 20% next year | Revenue: $1.146M FY2026-Q4; GAAP. Published target: >=36% YoY revenue growth. Target and observation units differ. Aug 19, 20261,145,802 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.06 → $-4.06 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-07-25 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-07-26 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-07-27 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-07-28 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-07-29 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-07-30 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-07-31 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-01 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-02 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-03 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-04 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-05 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-06 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-07 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-08 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-09 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-10 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-12 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-13 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-14 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-15 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-16 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-17 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-18 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-19 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-20 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-21 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-22 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-23 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-24 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-25 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-26 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-27 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-28 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-29 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-30 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-08-31 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-01 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-02 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-03 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-04 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-05 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-06 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-07 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-08 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-09 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-10 | $-4.06 | $8,820,000 | 1 / 1 |
| 2026-09-11 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-12 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-13 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-14 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-15 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-16 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-17 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-18 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-19 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-20 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-21 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-22 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-23 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-24 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-25 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-26 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-27 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-28 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-29 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-09-30 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-01 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-02 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-03 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-04 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-05 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-06 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-07 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-08 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-09 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-10 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-11 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-12 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-13 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-14 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-15 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-16 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-17 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-18 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-19 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-20 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-21 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-22 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-23 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-24 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-25 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-26 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-27 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-28 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-29 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-30 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-10-31 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-11-01 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-11-02 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-11-03 | $-4.06 | $8,800,000 | 1 / 1 |
| 2026-11-04 | $-4.06 | $8,800,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.